Study of zodasiran for teens with homozygous familial hypercholesterolemia
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an experimental medicine called zodasiran in teenagers who have a rare inherited condition that causes very high cholesterol. The goal is to see if it can lower cholesterol levels and reduce the risk of heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old (not yet 18).
- You weigh at least 35 kilograms (about 77 pounds).
- You have a confirmed diagnosis of homozygous familial hypercholesterolemia (HoFH), either by genetic testing or clinical criteria.
- Your LDL cholesterol (the 'bad' cholesterol) is at least 116 mg/dL at screening.
- Your blood sugar (HbA1c) is 9.5% or lower.
- Your liver function tests are within acceptable limits (bilirubin and enzymes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial continues to test a drug called SHR-1918, which may help lower very high cholesterol in people with a genetic condition called homozygous familial hypercholesterolemia. It looks at whether the drug remains effective and safe over a longer period of time.
This trial tests a one-time gene therapy to lower extremely high cholesterol in people with a rare inherited condition. It may help reduce heart attack risk in those who haven't responded to standard treatments.
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
This trial tests a new drug, EDP167, for people with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes very high cholesterol. The goal is to see if EDP167 can lower 'bad' cholesterol (LDL-C).
This trial tests a medicine called inclisiran to lower high cholesterol in children ages 6 to 12 with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It may help children who still have high cholesterol despite taking other treatments.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
Hear when a new Homozygous Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.